New research found that a specific subtype of a bacterium commonly found in the mouth and linked to gum disease was also present in 50% of colorectal cancer tumors that were studied by researchers.
Acurx Pharmaceuticals Inc. continues to post positive data for its lead candidate ibezapolstat but that didn’t stop the stock from tumbling. The antibiotic outperformed vancomycin in a phase IIb study treating Clostridioides difficile infection (CDI). Vancomycin is a standard of care in the indication. Ibezapolstat eradicated fecal CDI at day 3 in 15 of 16 patients compared to vancomycin, which eradicated fecal CDI in 10 of 14 patients.
joining me now is our medical editor, fergus walsh. how excited should we be by this? this is promising and a bit of good news. research published in the journal nature, its over 50 years since we had a new class of antibiotic against this type of bacterium. the book in question is resistant, acinetobacter baumannii, or crab for short. crab thrives in hospitals where patients are already immune suppressed. they may have blood infections, be in intensive care, and it has a mortality rate of around 50% because there are so few drugs to treat it. now, this particular antibiotic in trials in the labs and in mice, it killed the bacterium. now, in humans, we are a long way off from having a new one that we can use in hospitals, it